Soligenix Inc, (SNGX)

$6.07

-0.32

(-5.01%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $5.83
    $6.36
    $6.07
    downward going graph

    3.95%

    Downside

    Day's Volatility :8.33%

    Upside

    4.56%

    downward going graph
  • $1.83
    $19.20
    $6.07
    downward going graph

    69.85%

    Downside

    52 Weeks Volatility :90.47%

    Upside

    68.39%

    downward going graph

Returns

PeriodSoligenix Inc,Index (Russel 2000)
3 Months
-6.51%
0.0%
6 Months
-36.77%
0.0%
1 Year
-43.39%
0.0%
3 Years
-97.42%
-20.8%

Highlights

Market Capitalization
6.3M
Book Value
$1.17
Earnings Per Share (EPS)
-9.76
PEG Ratio
-1.52
Wall Street Target Price
41.5
Profit Margin
0.0%
Operating Margin TTM
-1809.03%
Return On Assets TTM
-50.0%
Return On Equity TTM
-23783.76%
Revenue TTM
699.2K
Revenue Per Share TTM
1.16
Quarterly Revenue Growth YOY
-54.50000000000001%
Gross Profit TTM
95.6K
EBITDA
-7.7M
Diluted Eps TTM
-9.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-8.2
EPS Estimate Next Year
-7.12
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Soligenix Inc,(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 583.69%

Current $6.07
Target $41.50

Technicals Summary

Sell

Neutral

Buy

Soligenix Inc, is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Soligenix Inc,
Soligenix Inc,
75.43%
-36.77%
-43.39%
-97.42%
-97.91%
Moderna, Inc.
Moderna, Inc.
-9.19%
21.5%
-4.18%
-62.27%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.99%
12.81%
44.78%
82.21%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.34%
24.69%
58.81%
196.23%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.88%
11.69%
35.62%
150.46%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Soligenix Inc,
Soligenix Inc,
NA
NA
-1.52
-8.2
-237.84
-0.5
NA
1.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Soligenix Inc,
Soligenix Inc,
Buy
$6.3M
-97.91%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Soligenix Inc,

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 244.81K → 117.02K (in $), with an average decrease of 52.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -1.04M → -1.91M (in $), with an average decrease of 18.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 102.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 196.2% return, outperforming this stock by 293.6%

Institutional Holdings

  • Geode Capital Management, LLC

    0.36%
  • Vanguard Group Inc

    0.32%
  • Nomura Holdings Inc

    0.19%
  • Warberg Asset Management LLC

    0.16%
  • First Wilshire Securities Mgmt Inc (CA)

    0.15%
  • Two Sigma Investments LLC

    0.08%

Company Information

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Organization
Soligenix Inc,
Employees
13
CEO
Dr. Christopher J. Schaber Ph.D.
Industry
Health Technology

FAQs